Deal Watch: Roche Wins Potential Blockbuster Esbriet In $8.3B Buyout Of InterMune
Executive Summary
While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.
You may also be interested in...
ASCEND Data Puts InterMune’s Pirfenidone On Top
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.